STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

HNGE insider filing: Hinge Health CFO reports open-market stock sales

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Hinge Health, Inc. (HNGE) Chief Financial Officer James Budge reported open-market sales of Class A common stock under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2025. On November 25, 2025, he sold 15,730 shares at a weighted average price of $46.8822, 27,248 shares at a weighted average price of $47.7669, and 1,611 shares at a weighted average price of $48.2738, across specified price ranges. Following these transactions, Budge beneficially owned 479,878 shares of Hinge Health Class A common stock in direct ownership.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Budge James

(Last) (First) (Middle)
C/O HINGE HEALTH, INC.
455 MARKET STREET, SUITE 700

(Street)
SAN FRANCISCO CA 94105

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Hinge Health, Inc. [ HNGE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
11/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 11/25/2025 S(1) 15,730 D $46.8822(2) 508,737 D
Class A Common Stock 11/25/2025 S(1) 27,248 D $47.7669(3) 481,489 D
Class A Common Stock 11/25/2025 S(1) 1,611 D $48.2738(4) 479,878 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025.
2. Represents the weighted average sale price. The lowest price at which shares were sold was $46.25 and the highest price at which shares were sold was $47.24. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
3. Represents the weighted average sale price. The lowest price at which shares were sold was $47.25 and the highest price at which shares were sold was $48.24. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
4. Represents the weighted average sale price. The lowest price at which shares were sold was $48.25 and the highest price at which shares were sold was $48.33. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
/s/ James Budge 11/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Hinge Health (HNGE) disclose in this Form 4?

The filing reports that Chief Financial Officer James Budge sold shares of Hinge Health, Inc. Class A common stock in open-market transactions on November 25, 2025.

How many HNGE shares did the CFO sell on November 25, 2025?

On November 25, 2025, James Budge sold 15,730, 27,248, and 1,611 shares of Hinge Health Class A common stock in three separate sale transactions.

At what prices were the Hinge Health (HNGE) shares sold by the CFO?

The reported sales were at weighted average prices of $46.8822, $47.7669, and $48.2738 per share, each within specified price ranges disclosed in the footnotes.

Does this Hinge Health Form 4 involve a Rule 10b5-1 trading plan?

Yes. The filing states that the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by James Budge on June 12, 2025.

How many HNGE shares does the CFO own after these transactions?

After the reported sales, James Budge beneficially owned 479,878 shares of Hinge Health Class A common stock, held directly.

What additional pricing detail is provided for the Hinge Health insider sales?

For each weighted average price, the filing discloses the lowest and highest sale prices in the range and notes that full breakdowns by price level are available upon request.
Hinge Health, Inc.

NYSE:HNGE

HNGE Rankings

HNGE Latest News

HNGE Latest SEC Filings

HNGE Stock Data

3.94B
34.45M
8.08%
132.02%
1.61%
Health Information Services
Services-computer Processing & Data Preparation
Link
United States
SAN FRANCISCO